13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <div class="section"> <a class="named-anchor" id="ab-joi180117-1"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e376">Question</h5> <p id="d5657406e378">For patients with severe obesity and type 2 diabetes, is there an association between bariatric surgery and incident macrovascular disease (defined as first occurrence of acute myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, ischemic stroke, hemorrhagic stroke, carotid stenting, or carotid endarterectomy)? </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-2"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e381">Findings</h5> <p id="d5657406e383">In this retrospective cohort study of patients with type 2 diabetes and severe obesity that included 5301 who underwent bariatric surgery and 14 934 control patients without surgery, bariatric surgery was associated with a significantly lower risk of macrovascular events at 5 years’ follow-up (2.1% vs 4.3% at 5 years; hazard ratio, 0.60). </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-3"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e386">Meaning</h5> <p id="d5657406e388">Bariatric surgery was associated with a lower risk of incident major macrovascular events. </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-4"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e392">Importance</h5> <p id="d5657406e394">Macrovascular disease is a leading cause of morbidity and mortality for patients with type 2 diabetes, and medical management, including lifestyle changes, may not be successful at lowering risk. </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-5"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e397">Objective</h5> <p id="d5657406e399">To investigate the relationship between bariatric surgery and incident macrovascular (coronary artery disease and cerebrovascular diseases) events in patients with severe obesity and type 2 diabetes. </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-6"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e402">Design, Setting, and Participants</h5> <p id="d5657406e404">In this retrospective, matched cohort study, patients with severe obesity (body mass index ≥35) aged 19 to 79 years with diabetes who underwent bariatric surgery from 2005 to 2011 in 4 integrated health systems in the United States (n = 5301) were matched to 14 934 control patients on site, age, sex, body mass index, hemoglobin A <sub>1c</sub>, insulin use, observed diabetes duration, and prior health care utilization, with follow-up through September 2015. </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-7"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e410">Exposures</h5> <p id="d5657406e412">Bariatric procedures (76% Roux-en-Y gastric bypass, 17% sleeve gastrectomy, and 7% adjustable gastric banding) were compared with usual care for diabetes. </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-8"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e415">Main Outcomes and Measures</h5> <p id="d5657406e417">Multivariable-adjusted Cox regression analysis investigated time to incident macrovascular disease (defined as first occurrence of coronary artery disease [acute myocardial infarction, unstable angina, percutaneous coronary intervention, or coronary artery bypass grafting] or cerebrovascular events [ischemic stroke, hemorrhagic stroke, carotid stenting, or carotid endarterectomy]). Secondary outcomes included coronary artery disease and cerebrovascular outcomes separately. </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-9"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e420">Results</h5> <p id="d5657406e422">Among a combined 20 235 surgical and nonsurgical patients, the mean (SD) age was 50 (10) years; 76% of the surgical and 75% of the nonsurgical patients were female; and the baseline mean (SD) body mass index was 44.7 (6.9) and 43.8 (6.7) in the surgical and nonsurgical groups, respectively. At the end of the study period, there were 106 macrovascular events in surgical patients (including 37 cerebrovascular and 78 coronary artery events over a median of 4.7 years; interquartile range, 3.2-6.2 years) and 596 events in the matched control patients (including 227 cerebrovascular and 398 coronary artery events over a median of 4.6 years; interquartile range, 3.1-6.1 years). Bariatric surgery was associated with a lower composite incidence of macrovascular events at 5 years (2.1% in the surgical group vs 4.3% in the nonsurgical group; hazard ratio, 0.60 [95% CI, 0.42-0.86]), as well as a lower incidence of coronary artery disease (1.6% in the surgical group vs 2.8% in the nonsurgical group; hazard ratio, 0.64 [95% CI, 0.42-0.99]). The incidence of cerebrovascular disease was not significantly different between groups at 5 years (0.7% in the surgical group vs 1.7% in the nonsurgical group; hazard ratio, 0.69 [95% CI, 0.38-1.25]). </p> </div><div class="section"> <a class="named-anchor" id="ab-joi180117-10"> <!-- named anchor --> </a> <h5 class="section-title" id="d5657406e425">Conclusions and Relevance</h5> <p id="d5657406e427">In this observational study of patients with type 2 diabetes and severe obesity who underwent surgery, compared with those who did not undergo surgery, bariatric surgery was associated with a lower risk of macrovascular outcomes. The findings require confirmation in randomized clinical trials. Health care professionals should engage patients with severe obesity and type 2 diabetes in a shared decision making conversation about the potential role of bariatric surgery in the prevention of macrovascular events. </p> </div><p class="first" id="d5657406e431">This cohort study investigates associations between bariatric surgery and incident macrovascular events (coronary artery and cerebrovascular diseases) in patients with type 2 diabetes. </p>

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

          Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin. The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79). A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent. Copyright 2003 Massachusetts Medical Society
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Long-term drug treatment for obesity: a systematic and clinical review.

            Thirty-six percent of US adults are obese, and many cannot lose sufficient weight to improve health with lifestyle interventions alone. To conduct a systematic review of medications currently approved in the United States for obesity treatment in adults. We also discuss off-label use of medications studied for obesity and provide considerations for obesity medication use in clinical practice. A PubMed search from inception through September 2013 was performed to find meta-analyses, systematic reviews, and randomized, placebo-controlled trials for currently approved obesity medications lasting at least 1 year that had a primary or secondary outcome of body weight change, included at least 50 participants per group, reported at least 50% retention, and reported results on an intention-to-treat basis. Studies of medications approved for other purposes but tested for obesity treatment were also reviewed. Obesity medications approved for long-term use, when prescribed with lifestyle interventions, produce additional weight loss relative to placebo ranging from approximately 3% of initial weight for orlistat and lorcaserin to 9% for top-dose (15/92 mg) phentermine plus topiramate-extended release at 1 year. The proportion of patients achieving clinically meaningful (at least 5%) weight loss ranges from 37% to 47% for lorcaserin, 35% to 73% for orlistat, and 67% to 70% for top-dose phentermine plus topiramate-extended release. All 3 medications produce greater improvements in many cardiometabolic risk factors than placebo, but no obesity medication has been shown to reduce cardiovascular morbidity or mortality. Most prescriptions are for noradrenergic medications, despite their approval only for short-term use and limited data for their long-term safety and efficacy. Medications approved for long-term obesity treatment, when used as an adjunct to lifestyle intervention, lead to greater mean weight loss and an increased likelihood of achieving clinically meaningful 1-year weight loss relative to placebo. By discontinuing medication in patients who do not respond with weight loss of at least 5%, clinicians can decrease their patients' exposure to the risks and costs of drug treatment when there is little prospect of long-term benefit.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.

              Controlling glycemia, blood pressure, and cholesterol is important for patients with diabetes. How best to achieve this goal is unknown. To compare Roux-en-Y gastric bypass with lifestyle and intensive medical management to achieve control of comorbid risk factors. A 12-month, 2-group unblinded randomized trial at 4 teaching hospitals in the United States and Taiwan involving 120 participants who had a hemoglobin A1c (HbA1c) level of 8.0% or higher, body mass index (BMI) between 30.0 and 39.9, C peptide level of more than 1.0 ng/mL, and type 2 diabetes for at least 6 months. The study began in April 2008. Lifestyle-intensive medical management intervention and Roux-en-Y gastric bypass surgery. Medications for hyperglycemia, hypertension, and dyslipidemia were prescribed according to protocol and surgical techniques that were standardized. Composite goal of HbA1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg. All 120 patients received the intensive lifestyle-medical management protocol and 60 were randomly assigned to undergo Roux-en-Y gastric bypass. After 12-months, 28 participants (49%; 95% CI, 36%-63%) in the gastric bypass group and 11 (19%; 95% CI, 10%-32%) in the lifestyle-medical management group achieved the primary end points (odds ratio [OR], 4.8; 95% CI, 1.9-11.7). Participants in the gastric bypass group required 3.0 fewer medications (mean, 1.7 vs 4.8; 95% CI for the difference, 2.3-3.6) and lost 26.1% vs 7.9% of their initial body weigh compared with the lifestyle-medical management group (difference, 17.5%; 95% CI, 14.2%-20.7%). Regression analyses indicated that achieving the composite end point was primarily attributable to weight loss. There were 22 serious adverse events in the gastric bypass group, including 1 cardiovascular event, and 15 in the lifestyle-medical management group. There were 4 perioperative complications and 6 late postoperative complications. The gastric bypass group experienced more nutritional deficiency than the lifestyle-medical management group. In mild to moderately obese patients with type 2 diabetes, adding gastric bypass surgery to lifestyle and medical management was associated with a greater likelihood of achieving the composite goal. Potential benefits of adding gastric bypass surgery to the best lifestyle and medical management strategies of diabetes must be weighed against the risk of serious adverse events. clinicaltrials.gov Identifier: NCT00641251.
                Bookmark

                Author and article information

                Journal
                JAMA
                JAMA
                American Medical Association (AMA)
                0098-7484
                October 16 2018
                October 16 2018
                : 320
                : 15
                : 1570
                Affiliations
                [1 ]The Permanente Medical Group, Kaiser Permanente Northern California, Oakland
                [2 ]Kaiser Permanente Washington Health Research Institute, Seattle
                [3 ]Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
                [4 ]Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena
                [5 ]HealthPartners Institute, HealthPartners, Minneapolis, Minnesota
                [6 ]RAND Corporation, Santa Monica, California
                [7 ]Institute for Health Research, Kaiser Permanente Colorado, Aurora
                [8 ]Division of Research, Kaiser Permanente Northern California, Oakland
                Article
                10.1001/jama.2018.14619
                6233803
                30326126
                7d3b4d0d-461b-47d5-8383-0f65de434575
                © 2018
                History

                Comments

                Comment on this article